255
Participants
Start Date
July 23, 2020
Primary Completion Date
July 26, 2021
Study Completion Date
July 26, 2021
TPN171H
Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
placebo
Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Peking University Third Hospital, Beijing
The First Affiliated Hospital of Dalian Medical University, Dalian
The First Hospital of Jilin University, Changchun
Nanjing Drum Tower Hospital, Nanjing
Second Affiliated Hospital of Suzhou University, Suzhou
The First Affiliated Hospital of Anhui Medical University, Hefei
The First Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Fujian Medical University, Fuzhou
The Third Xiangya Hospital of Central South University, Changsha
Henan Provincial People's Hospital, Zhengzhou
Guangzhou First People's Hospital, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
OTHER
Vigonvita Life Sciences
INDUSTRY